Big pharmaceutical companies facing patent cliffs. MedTech companies seeking access to the latest AI technologies. Across the life sciences industry, companies have strong incentives to use M&A to grow their product pipelines, enhance their existing product offerings, and gain access to new markets. But, at what cost? Less than half of phase II clinical trials succeed, and phase III clinical trials are far from a sure thing. Roughly 75% of medical device start-ups ultimately fail. Even if a new drug or device ultimately achieves regulatory approval, its commercial performance is uncertain. Simply put, acquiring early-stage life sciences targets is a risky business. This article explores strategies to mitigate risk in life sciences acquisitions.
Read the full article: Mitigating Risk in Life Sciences Acquisitions //
Source: https://www.lexology.com/library/detail.aspx?g=1a0efef7-59ac-4c27-8516-16310a7d5d9f